Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Other Non Operating Income (2016 - 2025)

Collegium Pharmaceutical has reported Other Non Operating Income over the past 5 years, most recently at -$16.0 million for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$16.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$16.0 million (down 41.18% YoY), and the annual figure for FY2025 was -$16.0 million, down 41.18%.
  • Other Non Operating Income for Q4 2025 was -$16.0 million at Collegium Pharmaceutical, down from -$4.1 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for COLL hit a ceiling of $23.5 million in Q1 2023 and a floor of -$47.0 million in Q2 2023.
  • Median Other Non Operating Income over the past 3 years was -$7.2 million (2024), compared with a mean of -$10.2 million.
  • Peak annual rise in Other Non Operating Income hit 84.72% in 2024, while the deepest fall reached 84.72% in 2024.
  • Collegium Pharmaceutical's Other Non Operating Income stood at -$47.0 million in 2023, then skyrocketed by 91.18% to -$4.1 million in 2024, then tumbled by 285.86% to -$16.0 million in 2025.
  • The last three reported values for Other Non Operating Income were -$16.0 million (Q4 2025), -$4.1 million (Q3 2024), and -$7.2 million (Q2 2024) per Business Quant data.